NGM stock holds at USD 1.50 as cash remains central

Published on 09/23/2026 at 04:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NGM stock was quoted at USD 1.50 on September 23, 2026, while its cash position remains central to valuation. Clinical progress is the next key test.

NGM, US62921N1006, Illustration mit AI erstellt.

NGM stock was quoted at USD 1.50 on the Nasdaq on September 23, 2026. The price data provide the clearest measurable reference for NGM Bio (ISIN US62921N1006), while the company remains a clinical-stage biotechnology business whose valuation depends on development progress and available funding.

Price sets the market reference

At USD 1.50 on September 23, 2026, the shares offered a dated market value for the latest completed quotation. The stock's market capitalization was USD 11.7 million on the same date, giving investors a direct measure of the equity value assigned to the company.

The comparison between the USD 1.50 share price and the USD 11.7 million market capitalization also underlines the scale of the equity base: the company is valued at a small-cap level where clinical data, financing conditions and dilution risk can outweigh conventional earnings metrics.

Clinical progress drives valuation

NGM's investment case is tied to research and development rather than recurring commercial revenue. For the latest reported period available through September 23, 2026, the company had no commercial product revenue and continued to report a net loss as it funded its pipeline.

That operating profile makes cash and research milestones more important than sales growth. A clinical-stage company with USD 11.7 million in market value can show large percentage changes from relatively small financing, licensing or trial updates, so the USD 1.50 quotation should be read together with the company's development timetable and funding needs.

NGM stock closes at USD 1.50

NGM stock stood at USD 1.50 on the Nasdaq as of September 23, 2026. The dated price and USD 11.7 million market capitalization form the current market baseline for assessing future clinical and financing announcements.